FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387157597> ?p ?o ?g. }

• W4387157597 abstract "The mTOR inhibitor, everolimus, is an important clinical management component of metastatic ER+ breast cancer (BC). However, most patients develop resistance and progress on therapy, highlighting the need to discover strategies that increase mTOR inhibitor effectiveness. We developed ER+ BC cell lines, sensitive or resistant to everolimus, and discovered that combination treatment of ONC201/TIC10 with everolimus inhibited cell growth in 2D/3D in vitro studies. We confirmed increased therapeutic response in primary patient cells progressing on everolimus, supporting clinical relevance. We show that ONC201/TIC10 mechanism in metastatic ER+ BC cells involves oxidative phosphorylation inhibition and stress response activation. Transcriptomic analysis in everolimus resistant breast patient tumors and mitochondrial functional assays in resistant cell lines demonstrated increased mitochondrial respiration dependency, contributing to ONC201/TIC10 sensitivity. We propose that ONC201/TIC10 and modulation of mitochondrial function may provide an effective add-on therapy strategy for patients with metastatic ER+ BCs resistant to mTOR inhibitors.Breast cancer is one of the most frequently diagnosed cancers globally, particularly among women. The most common type of breast cancer expresses a receptor for the hormone estrogen. Many treatments block the activity of estrogen and therefore slow or block the development and spread of this type of breast cancer. For patients with advanced breast cancer, hormone-blocking treatments work best in combination with other drugs, including one called everolimus. However, in many patients the cancer cells become resistant to these therapies, leading to disease progression and decreased survival. To explore treatment strategies that could enhance the effectiveness of existing therapies for breast cancer, Farmaki et al. studied how cancer cells which had become resistant to everolimus responded when treated with an experimental drug called ONC201/TIC10. A combination of everolimus and ONC201/TIC10 inhibited growth of resistant cancer cells that had been grown in a three-dimensional arrangement to mimic human tumors. Moreover, the drug combination effectively targeted breast cancer cells collected from patients whose cancer had progressed while being treated with everolimus, suggesting that ONC201/TIC10 could be relevant in a clinical setting. Finally, molecular and biochemical experiments revealed that the drug ONC201/TIC10 works by disrupting the pathways that everolimus-resistant cancer cells use to generate the energy required to grow and proliferate. Taken together these findings suggest that ONC201/TIC10 may provide an effective add-on therapy for patients with certain types of advanced breast cancer that are no longer responding to everolimus. Before this becomes a reality for patients, however, there will have to be more experimental testing of ONC201/TIC10 to determine optimal dosing and timing strategy for future clinical trials." @default.
• W4387157597 created "2023-09-30" @default.
• W4387157597 creator A5009406892 @default.
• W4387157597 creator A5052560792 @default.
• W4387157597 creator A5058032643 @default.
• W4387157597 creator A5059442457 @default.
• W4387157597 creator A5060960481 @default.
• W4387157597 creator A5072788736 @default.
• W4387157597 creator A5086983885 @default.
• W4387157597 date "2023-09-29" @default.
• W4387157597 modified "2023-10-03" @default.
• W4387157597 title "ONC201/TIC10 enhances durability of mTOR inhibitor everolimus in metastatic ER+ breast cancer" @default.
• W4387157597 cites W1603456871 @default.
• W4387157597 cites W1828795946 @default.
• W4387157597 cites W1980324695 @default.
• W4387157597 cites W1994673501 @default.
• W4387157597 cites W1995197723 @default.
• W4387157597 cites W1998203489 @default.
• W4387157597 cites W2010457001 @default.
• W4387157597 cites W2019043300 @default.
• W4387157597 cites W2024841712 @default.
• W4387157597 cites W2026125986 @default.
• W4387157597 cites W2038252997 @default.
• W4387157597 cites W2045810780 @default.
• W4387157597 cites W2058669819 @default.
• W4387157597 cites W2059755711 @default.
• W4387157597 cites W2062620611 @default.
• W4387157597 cites W2070788611 @default.
• W4387157597 cites W2073973240 @default.
• W4387157597 cites W2089668045 @default.
• W4387157597 cites W2098791934 @default.
• W4387157597 cites W2100885424 @default.
• W4387157597 cites W2101122879 @default.
• W4387157597 cites W2117357260 @default.
• W4387157597 cites W2133644385 @default.
• W4387157597 cites W2162606162 @default.
• W4387157597 cites W2167188058 @default.
• W4387157597 cites W2278250712 @default.
• W4387157597 cites W2283948643 @default.
• W4387157597 cites W2310326452 @default.
• W4387157597 cites W2465456790 @default.
• W4387157597 cites W2515940974 @default.
• W4387157597 cites W2562573190 @default.
• W4387157597 cites W2590156059 @default.
• W4387157597 cites W2606094885 @default.
• W4387157597 cites W2739350405 @default.
• W4387157597 cites W2742971656 @default.
• W4387157597 cites W2773577558 @default.
• W4387157597 cites W2791017844 @default.
• W4387157597 cites W2792509718 @default.
• W4387157597 cites W2794978585 @default.
• W4387157597 cites W2795439598 @default.
• W4387157597 cites W2802055554 @default.
• W4387157597 cites W2884482864 @default.
• W4387157597 cites W2907544909 @default.
• W4387157597 cites W2941632024 @default.
• W4387157597 cites W2943151208 @default.
• W4387157597 cites W2946288516 @default.
• W4387157597 cites W3008637313 @default.
• W4387157597 cites W3010239507 @default.
• W4387157597 cites W3010743969 @default.
• W4387157597 cites W3036304621 @default.
• W4387157597 cites W3093671722 @default.
• W4387157597 cites W3158572124 @default.
• W4387157597 cites W3160255881 @default.
• W4387157597 cites W3163961394 @default.
• W4387157597 cites W3168033772 @default.
• W4387157597 cites W3200632075 @default.
• W4387157597 cites W3207531893 @default.
• W4387157597 cites W3216027570 @default.
• W4387157597 cites W4206896208 @default.
• W4387157597 cites W4220657028 @default.
• W4387157597 cites W4287462021 @default.
• W4387157597 cites W4294955997 @default.
• W4387157597 cites W636925189 @default.
• W4387157597 doi "https://doi.org/10.7554/elife.85898" @default.
• W4387157597 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37772709" @default.
• W4387157597 hasPublicationYear "2023" @default.
• W4387157597 type Work @default.
• W4387157597 citedByCount "0" @default.
• W4387157597 crossrefType "journal-article" @default.
• W4387157597 hasAuthorship W4387157597A5009406892 @default.
• W4387157597 hasAuthorship W4387157597A5052560792 @default.
• W4387157597 hasAuthorship W4387157597A5058032643 @default.
• W4387157597 hasAuthorship W4387157597A5059442457 @default.
• W4387157597 hasAuthorship W4387157597A5060960481 @default.
• W4387157597 hasAuthorship W4387157597A5072788736 @default.
• W4387157597 hasAuthorship W4387157597A5086983885 @default.
• W4387157597 hasBestOaLocation W43871575971 @default.
• W4387157597 hasConcept C121608353 @default.
• W4387157597 hasConcept C126322002 @default.
• W4387157597 hasConcept C143998085 @default.
• W4387157597 hasConcept C190283241 @default.
• W4387157597 hasConcept C2775860665 @default.
• W4387157597 hasConcept C2775930923 @default.
• W4387157597 hasConcept C2776166826 @default.
• W4387157597 hasConcept C2779699572 @default.
• W4387157597 hasConcept C502942594 @default.
• W4387157597 hasConcept C530470458 @default.
• W4387157597 hasConcept C55493867 @default.

• next